

Important Notes 重要提示

- 1 Manulife Advanced Fund SPC - China A Segregated Portfolio (the "Fund"), which is denominated in United States Dollars ("USD") rather than Renminbi ("RMB"), to primarily invest directly in RMB-denominated China A-shares.
- 2 RMB is not freely convertible and is subject to exchange controls and restrictions. There is no guarantee that RMB will not depreciate. There are various requirements and restrictions under the laws of Mainland China and regulations relating to investment via QFII regime that may expose the Fund to higher volatility, liquidity, emerging market and Mainland China tax and custodial risks.
- 3 In the worst case scenario, the Fund may suffer significant loss potentially equal to all their investments in Mainland China domestic securities.
- 4 Investment involves risk. Investors should not invest solely based on this material and should read the offering document for details including the risk factors, charges and features of the Fund.

- 1 宏利盈進基金SPC - 中國A股獨立資產組合(「本基金」)以美元計價，而不是以人民幣計價，主要直接投資於以人民幣計價的A股。
- 2 人民幣不是自由兌換的貨幣並受到外匯管制和限制。沒有保證人民幣不貶值。中國內地於QFII制度的法規有各種要求和限制，使本基金承受波動性、流動性、新興市場、中國內地稅務及託管的相關風險。
- 3 在最壞的情況下，本基金可能遭受等於其在中國內地證券所有投資的損失。
- 4 投資涉及風險。投資者不應只單靠本資料而作出投資，而應仔細閱讀銷售文件，以獲取詳細資料，包括本基金之風險因素、收費及產品特點。

Fund prices may go down as well as up. Past performance information presented are not indicative of future performance. Investor has his/her own personal investment objectives, investment products may not be suitable for everyone.

基金價格可跌亦可升，過往業績數據並非未來業績的指標。投資者的目標各有不同，投資產品未必適合所有投資者。

This material has not been reviewed by the Securities and Futures Commission.

證券及期貨事務監察委員會並未有審閱此文件。

Issued by Manulife Investment Management (Hong Kong) Limited.

由宏利投資管理（香港）有限公司刊發。

Scan the QR code for fund documents

查閱基金文件請掃描二維碼



Information as of 資料截至 2025/03/31

Investment Objective 投資目標

To achieve long-term capital appreciation by investing primarily in Mainland China capital markets. The fund seeks to achieve its investment objective by investing primarily (i.e. not less than 70% of its net assets) in companies listed on the A-Share markets of the Shanghai Stock Exchange and/or the Shenzhen Stock Exchange.

基金旨在著重投資於中國內地資本市場以達致長期資本增長。基金將透過主要投資(即其淨資產的70%)於在上海證券交易所及/或深圳證券交易所A股市場上市的公司，尋求達致其投資目標。

Fund Information 基金資料

Investment Manager 投資管理人	Manulife Investment Management (Hong Kong) Limited 宏利投資管理(香港)有限公司		
Launch Date (YYYY/MM/DD) 發行日期	2010/11/08		
Launch Price (per share) 發行價格(每股)	USD 10.00		
Base Currency 基礎貨幣	USD 美元		
Available Class(es) and their Bloomberg/ISIN Code 可選擇之類別及其彭博/ISIN編號	Bloomberg Ticker 彭博編號	ISIN Code ISIN編號	
Class AA (USD) AA(美元)類別	MANCSAA	KYG5800M1050	
Fund Size 基金規模	USD 22.16 million 百萬		
Initial Charge [†] 初次收費 [†]	Up to 5.00% 最多達5.00%		
Switching Charge 轉換費	No switching is allowed 不准轉換		
Management Fee [†] 管理費 [†]	1.50% per annum of the NAV of this fund 每年本基金資產淨值的 1.50%		
Minimum Initial Investment 最低初次投資額	HKD 20,000		
Minimum Subsequent Investment 最低其後投資額	HKD 1,000		
Net Asset Value (NAV) Per Share 每股資產淨值	USD 11.3160 (Class AA (USD) AA(美元)類別)		
Benchmark ^{^^} 基準指數 ^{^^}	MSCI China A Onshore Index MSCI 中國A 股在岸指數		
Standard Deviation (3 Years) 標準差(三年)	24.27%		

Calendar Year Performance 年度表現

	2024	2023	2022	2021	2020
Class AA (USD) AA(美元)類別	11.84%	-10.07%	-33.07%	3.93%	42.36%
Benchmark 基準指數	11.59%	-11.65%	-26.75%	-2.72%	35.50%

Cumulative Performance 累積表現

	YTD 年初至今	3 months 三個月	1 yr. 一年	3 yrs. 三年	5 yrs. 五年	Since Launch 成立至今
Class AA (USD) AA(美元)類別	4.28%	4.28%	20.35%	-10.49%	13.15%	13.16%
Benchmark 基準指數	0.10%	0.10%	12.47%	-15.82%	7.83%	7.00%

5-Year Cumulative Performance 五年累積表現**Top Holdings 主要持有成份**

Sichuan Kelun Pharmaceutical Co., Ltd.	4.63%
Kweichow Moutai Co., Ltd.	3.18%
Hongfa Technology Co., Ltd.	3.02%
Jiangsu Hengli Hydraulic Co., Ltd.	2.86%
Aluminum Corporation of China Limited	2.84%
CMOC Group Limited	2.78%
Ping An Bank Co. Ltd.	2.63%
China Life Insurance Co. Ltd.	2.36%
Jiangsu Hengrui Pharmaceuticals Co., Ltd.	2.31%
GoerTek Inc.	2.31%

Geographical Breakdown⁻**地區分佈⁻**

China 中國	99.32%
Cash & Cash Equivalents 現金及現金等值資產	0.68%

Sector Breakdown⁻**類別分佈⁻**

Information Technology 資訊科技	22.15%
Financials 金融	19.68%
Industrials 工業	16.79%
Materials 物料	10.72%
Consumer Discretionary 非日常生活消費品	8.66%
Healthcare 醫療保健	7.87%
Consumer Staples 日常消費品	6.20%
Communication Services 通訊服務	3.37%
Others 其他	3.88%
Cash & Cash Equivalents 現金及現金等值資產	0.68%

Source: Manulife Investment Management (Hong Kong) Limited unless otherwise indicated. All the performance figures are on NAV to NAV basis, in base currency with dividends reinvested. The sourced information contained herein is not warranted to be accurate, complete or timely. Neither Manulife Investment Management (Hong Kong) Limited nor any of its affiliates are responsible for any damages or losses arising from any use of this information. 資料來源：宏利投資管理(香港)有限公司或另有說明。所有的業績數據以資產淨值對資產淨值及基礎貨幣計算，股息再投資。本文件內所提供的資料並未就其準確性、完整性、及時間性作出保證。宏利投資管理(香港)有限公司及其任何聯繫公司均不負責任何因使用該等資料而引致的損害及損失。

[†] With effect as from 1 September 2022, the annual management fee was reduced from 1.75% to 1.50%. Manulife Investment Management (Hong Kong) Limited reserves the right to increase the fees up to a specified permitted maximum by giving affected unitholders at least one month's prior notice. Please refer to the Fund prospectus for details. 自2022年9月1日起生效，每年管理費由1.75%下調至1.50%。宏利投資管理(香港)有限公司保留權利，可向受影響的股東發出最少一個月事先通知情況下，將費用提高至最高的准許額度。詳情請參閱本基金的基金章程。

^{^^} The benchmark was changed from 70% CSI 300 Index + 30% MSCI Zhonghua Index to CSI 300 Index in February 2011 and to the current one in April 2022. 於2011年2月，基準指數由70%滬深300指數+30%摩根士丹利中華指數更改至滬深300指數，並於2022年4月更改至現時之指數。

⁻ Due to rounding, the total may not be equal to 100%. A negative percentage, if any, represents a short position in the portfolio for hedging/cash flow management purposes. Please refer to offering document of the Fund for details. 數字經修整後，總計可能並不相等於100%。負數百分比(如有)代表投資組合為了對沖或現金流管理而持有短倉。有關詳情請參閱本基金之銷售文件。

This fund invests in emerging markets and a single geographic region which may involve interest rate, liquidity, volatility, regulatory, political, concentration and RMB currency risks. Investment by using a QFII quota may expose the fund to QFII risks. Investors may expose to a high risk of capital loss. 本基金投資於新興市場及單一地區，可能涉及利率、流動性、波動性、規管、政治、集中性及人民幣貨幣風險，沒有保證人民幣不貶值。透過QFII 額度投資使本基金承受QFII 風險。投資者可能承受高度的資本虧損風險。